Marcus Blackmore is trying to move on. The 23 per cent shareholder in Australia’s big ASX-listed vitamins company Blackmores is feeling much better about a thawing in what were frosty relations with the board.

But he’s still grumpy about the share price, which is less than half the level of a golden age in late 2015-16 when it soared above $200 on huge demand from Chinese consumers.